Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium-Reference-Cited by-同舟云学术

Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium

Published:2014-03 Issue:3 Volume:167 Page:292-300
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Sager Philip T.,Gintant Gary,Turner J. Rick,Pettit Syril,Stockbridge Norman

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference31 articles.

1. New precompetitive paradigms: focus on cardiac safety;Finkle;Am Heart J,2009

2. Integrated and translational nonclinical in vivo cardiovascular risk assessment: gaps and opportunities;Berridge;Regul Toxicol Pharmacol,2013

3. Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes;Sager;Br J Pharmacol,2008

4. Dealing with global safety issues: was the response to QT-liability of non-cardiac drugs well coordinated?;Stockbridge;Drug Saf,2013

5. Fifteen years of cardiac safety: history, state-of-the-art research, and glimpses into the future. 2013;Turner;International Pharmaceutical Industry,2013

Cited by 475 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CardioGenAI: A Machine Learning-Based Framework for Re-Engineering Drugs for Reduced hERG Liability;2024-09-10

2. Applications of Single-Cell Omics Technologies for Induced Pluripotent Stem Cell-Based Cardiovascular Research;International Journal of Stem Cells;2024-08-12

3. Multiple hERG channel blocking pathways: implications for macromolecules;Trends in Pharmacological Sciences;2024-08

4. Drug safety assessment by machine learning models;Journal of Biopharmaceutical Statistics;2024-06-18

5. Using induced pluripotent stem cells for drug discovery in arrhythmias;Expert Opinion on Drug Discovery;2024-06-02